ClinicalTrials.gg
WithdrawnNCT04965272CAR aGAD Ph 2Updated Apr 12, 2022

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

A Phase 2 interventional study of Cariprazine 0.75 mg/day and Cariprazine 1.5 mg/day in Generalized Anxiety Disorder, sponsored by AbbVie. Withdrawn at 36 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Strategic Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
230th of 234
0 · median 90
Started
2021
with 13 others
Phase 2
21 of 265
5 open now
Registered
193rd of 265
by date
Lead sponsor
5 of 265
AbbVie

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 230th largest by enrollment of the 234 interventional ones that give a count, is one of 14 that started in 2021, is one of 21 in phase 2, and was the 193rd registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess adverse events and the change in disease activity with cariprazine when added to ADTs compared with placebo in adult participants with GAD who have had an inadequate response to 1 or more prior ADTs alone.

Cariprazine is an approved drug being developed for the treatment of GAD. The participants are placed into 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Around 1072 participants age 18-65 with GAD and an inadequate response to ADT alone will be enrolled in the study in the United States.

After a 2-week screening period, participants will receive daily oral capsules of cariprazine of varying doses or placebo for 6 weeks, followed by a 4-week safety follow-up period for a total study duration of 10 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder (GAD)
  • Cariprazine
  • Vraylar
  • Depression
  • Antidepressant therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with generalized anxiety disorder (GAD).
  • Taking one of the FDA-approved antidepressant therapies (ADTs) for the treatment of GAD (i.e., escitalopram, paroxetine, duloxetine, and venlafaxine XR).
  • Continuing to exhibit anxiety symptoms (Hamilton Anxiety Scale [HAM-A] total score >= 22) at Visit 1 (Screening) and Visit 2 (Baseline, Week 0) despite being on an adequate dose and duration (at least 6 weeks of continuous use, with a minimum of 3 of 6 weeks above the minimum labeled dose for GAD).
  • Documentation of inadequate response to at least 1 ADT must be confirmed on the GAD-Antidepressant Treatment Response Questionnaire (GAD-ATRQ).
  • Must have a minimum score of 22 on the rater-administrated HAM-A and a minimum score of 4 on the rater-administered Clinical Global Impression of Severity Scale (CGI-S), at both Visit 1 (Screening) and Visit 2 (Baseline, Week 0).
  • A score of less than 12 on the rater-administered Hamilton Depression Rating Scale-17-item (HAMD-17) at Visit 1 (Screening) and Visit 2 (Baseline, Week 0).
  • Laboratory values must meet the criteria specified in the protocol within the screening period prior to the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Psychiatric comorbidities, risk of suicide, self-injury, and/or harm to others; any current - 5th edition (DSM-5) psychiatric diagnosis other than generalized anxiety disorder (GAD) (other than specific phobias) or history of alcohol or any other substance-related disorders within the 6 months before Visit 1 (Screening).
  • Pregnancy, current breastfeeding status, plans to become pregnant or to donate eggs during the study or for approximately 30 days after the last dose of product (female participants).
  • History of an allergic reaction, , or intolerance to constituents of cariprazine (and its ) and/or other products of the same class or to any of the protocol-approved rescue medications.
  • Any or significant (ECG) abnormalities, including ECG with corrected for heart rate (QTc) using Fridericia's formula (QTcF) >450 msec (males) or >470 msec (females).
  • History of seizure disorder, with the exception of febrile seizure, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes to seizure.
  • Specific medical conditions precluding study drug use and/or study participation, such as history of neuroleptic malignant syndrome; cataracts or retinal detachment; allergic reactions/hypersensitivity to cariprazine and/or protocol-approved rescue medications; pregnancy per above; cardiovascular disease; seizure history; and any other disease that is clinically unstable or would make the participant an unsuitable candidate to participate in the study, based on the investigator's judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cariprazine 0.75 mg/day + Antidepressant Therapy

    Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 0.75 mg/day oral, once daily for 6 weeks

    Drug: Cariprazine 0.75 mg/day

  • Experimental
    Cariprazine 1.5 mg/day + Antidepressant Therapy

    Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral, once daily for 6 weeks

    Drug: Cariprazine 1.5 mg/day

  • Experimental
    Cariprazine 3.0 mg/day + Antidepressant Therapy

    Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral for 2 weeks followed by cariprazine 3.0 mg/day oral, once daily for 4 weeks.

    Drug: Cariprazine 3.0 mg/day

  • Placebo comparator
    Placebo + Antidepressant Therapy

    Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + oral placebo, once daily for 6 weeks

    Other: Placebo

Interventions

  • DrugCariprazine 0.75 mg/day

    Drug page: Cariprazine

    Oral Capsule

    Also known as: Vraylar

  • DrugCariprazine 1.5 mg/day

    Drug page: Cariprazine

    Oral Capsule

    Also known as: Vraylar

  • DrugCariprazine 3.0 mg/day

    Drug page: Cariprazine

    Oral Capsule

    Also known as: Vraylar

  • OtherPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.

    Time frame: Week 6

Secondary outcomes

  1. Change from Baseline in Clinical Global Impression of Severity Scale (CGI-S)

    The CGI-S is a single, clinician-reported item that measures the clinician's impression of a subject's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 5-point Likert rating scale, with higher scores indicating greater anxiety severity.

    Time frame: Week 6

  2. Percentage of Participants in Remission

    Remission is defined as HAM-A total score \<=7, Clinical Global Impression of Improvement Scale (CGI-I) = 1, and Sheehan Disability Scale: Anxiety (SDS: Anxiety) total score \<= 5

    Time frame: Week 6

  3. Percentage of Participants with HAM-A Response

    HAM-A response is defined as \>= 50% reduction from baseline in HAM-A total score

    Time frame: Week 6

  4. Percentage of Participants with CGI-I Responder Status of "Much Better" or "Very Much Better"

    The CGI-I is a single, clinician reported item that measures the clinician's impression of how much a participant's anxiety has changed since starting the study medication compared to the participant's condition at baseline. The measure uses a 7-point Likert rating scale with responses ranging from "very much better" (1) to "very much worse" (7).

    Time frame: Week 6

  5. Percentage of Participants with Patient Global Impression of Change Scale (PGI-C) Responder Status of "Much Better" or "Very Much Better"

    The PGI-C is a single, patient-reported item that assesses the participant's perceived overall change in their anxiety since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "very much better" (1) to "very much worse" (7).

    Time frame: Week 6

  6. Change from Baseline in Patient Global Impression of Severity Scale (PGI-S)

    The PGI-S is a single, patient-reported item that assesses the participant's perceived level of anxiety over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "none" (1) to "very severe" (5), with higher scores indicating greater anxiety severity.

    Time frame: Week 6

  7. Change from Baseline in SDS: Anxiety Total Score

    The SDS: Anxiety is a 5-item, patient-reported measure used to assess functional impairment in the domains of work/school, social life, and family life on a 10-point numeric rating scale with verbal anchors. The 3 items assessing work/school, social life, and home life or family responsibilities impairment are summed into a single dimensional measure of global functional impairment, with scores ranging from 0 (unimpaired) to 30 (highly impaired). Higher scores indicate greater impairment.

    Time frame: Week 6

  8. Change from Baseline in Hamilton Depression Rating Scale-17 item, via Structured Interview Guide for the Hamilton Depression Scale (HAMD-17) Total Score

    The HAMD-17 is a 17-item, clinician-reported measure used to quantify and categorize the participant's depression over the past week. The HAMD-17 total score ranges from 0 to 52 with higher scores indicating greater depression severity.

    Time frame: Week 6

07

Study locations

36 sites
  • Preferred Research Partners /ID# 232286
    Little Rock, Arkansas 72211, United States
  • Axiom Research /ID# 230728
    Colton, California 92324, United States
  • ATP Clinical Research, Inc /ID# 230445
    Costa Mesa, California 92626-4607, United States
  • ProScience Research Group /ID# 231520
    Culver City, California 90230-6632, United States
  • WR-PRI, LLC - Encino /ID# 230434
    Encino, California 91316, United States
  • Synergy San Diego /ID# 231006
    Lemon Grove, California 91945-2956, United States
  • Pharmacology Research Institute - Wake LLC /ID# 230722
    Los Alamitos, California 90720-3500, United States
  • Pharmacology Research Inst /ID# 230869
    Newport Beach, California 92660, United States
  • Anderson Clinical Research /ID# 230440
    Redlands, California 92374-4555, United States
  • California Neuroscience Research Medical Group, Inc. /ID# 230453
    Sherman Oaks, California 91403-2109, United States
  • Viking Clinical Research /ID# 230379
    Temecula, California 92591-6200, United States
  • Pacific Clinical Research Management Group /ID# 229725
    Upland, California 91786-3676, United States
  • Galiz Research - Palmetto Medical Plaza /ID# 230446
    Hialeah, Florida 33016, United States
  • Great Lakes Clinical Trials /ID# 231296
    Chicago, Illinois 60640, United States
  • Baber Research Group /ID# 230447
    Naperville, Illinois 60563-6502, United States
  • Boston Clinical Trials /ID# 231003
    Boston, Massachusetts 02131-2515, United States
  • ActivMed Practices and Research, LLC. /ID# 230441
    Methuen, Massachusetts 01844, United States
  • Alivation Research /ID# 230449
    Lincoln, Nebraska 68526-9474, United States
  • Center for Emotional Fitness /ID# 230450
    Cherry Hill, New Jersey 08002-3008, United States
  • Hassman Research Institute Marlton /ID# 233252
    Marlton, New Jersey 08053-1930, United States
  • Integrative Clinical Trials /ID# 230955
    Brooklyn, New York 11229-3576, United States
  • SPRI Clinical Trails /ID# 230957
    Brooklyn, New York 11235-5660, United States
  • Fieve Clinical Research, Inc. /ID# 230452
    New York, New York 10017-1921, United States
  • Clinilabs, Inc. /ID# 230958
    New York, New York 10019, United States
  • Manhattan Behavioral Medicine PLLC /ID# 229713
    New York, New York 10036, United States
  • Carolina Institute for Clinical Research - Fayetteville /ID# 230961
    Fayetteville, North Carolina 28303, United States
  • Ohio State Harding Hospital /ID# 231302
    Columbus, Ohio 43210-1250, United States
  • CincyScience /ID# 229719
    West Chester, Ohio 45069, United States
  • Sooner Clinical Research /ID# 229731
    Oklahoma City, Oklahoma 73112, United States
  • Research Strategies of Memphis /ID# 230443
    Memphis, Tennessee 38119-5202, United States
  • Clinical Neuroscience Solutions - Memphis /ID# 230734
    Memphis, Tennessee 38119, United States
  • Austin Clinical Trial Partners /ID# 229727
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas, LP /ID# 230535
    Dallas, Texas 75231, United States
  • Earle Research /ID# 230969
    Houston, Texas 77058-2746, United States
  • Grayline Research Center /ID# 230455
    Wichita Falls, Texas 76309-1608, United States
  • Woodstock Research Center /ID# 231005
    Woodstock, Vermont 05091-9795, United States
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2021
First posted
Jul 16, 2021
StartEst.
Aug 18, 2021
Primary completionActual
Aug 24, 2021
CompletionActual
Aug 24, 2021
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04965272
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Aug 18, 2021 (estimated)
Primary completion
Aug 24, 2021
Completion
Aug 24, 2021
Last update
Apr 12, 2022

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion